Country: Australia
Bahasa: Inggeris
Sumber: Department of Health (Therapeutic Goods Administration)
irinotecan hydrochloride trihydrate, Quantity: 500 mg
Medis Pharma Pty Ltd
irinotecan hydrochloride trihydrate
Injection, concentrated
Excipient Ingredients: sorbitol; lactic acid; sodium hydroxide; hydrochloric acid; water for injections
Intravenous Infusion
One
(S4) Prescription Only Medicine
Indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. Also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy
Visual Identification: Irinotecan is supplied in brown type 1 glass vial, containing a clear to pale yellow solution, stoppered by a bromobutylic rubber stopper and sealed with a aluminium crimp and a propylene disc.; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
2011-07-11